Applied Research Projects in Dementia: Validation of the Profile for Communication Abilities in Dementia (P-CAD).
Project Aim(s): To validate a cognitive communication assessment for people with dementia.
Project Aim(s): To validate a cognitive communication assessment for people with dementia.
Project Aim(s): To test a software engine designed to optimize medication in multimorbid older patients aimed at preventing unplanned hospitral readmissions.
Project Aim(s): To test a software engine for the prevention of adverse drug reactions in multimorbid older patients hospitalized with acute illness.
Project Aim(s): To examine how Ataxin-2 and Stress_Granule Modulatory Proteins function in ALS/FTD.
Project Aim(s): Development of optimally informative biomarkers for ALS, and establishment of stakeholder agreement regarding their use. This will be achieved by defining, validating and harmonizing optimal methodologies that can be reliably implemented within a pan-European framework program.
Project Aim(s): To discover new causative and disease-modifying pathways to pave the way for novel therapies.
Project Aim(s): This project aimed to utilize data from the Irish Register and the national ALS service to generate a framework for care for Irish ALS patients based on their clinical phenotype, rate of progression and long term prognosis. The objective was to design, estimate the costs, and measure the benefits of a multifaceted care programme that incorporates the key clinical and prognostic elements of ALS.
Project Aim(s): The aim is to use epidemiologic and clinical datasets to track in detail the patient journey in ALS, and from this to provide a robust staging system, generate cost models and appropriate health economic metrics, and to inform the design of a user-friendly electronic care matrix for optimal ALS management that can be used by non-specialists, and that in turn can be modified for use in other neurodegenerative conditions.
Project Aim(s):
(i) To continue to characterise the clinical subphenotypes of ALS and to further elucidate the observed clinical and genetic overlap between ALS and neuropsychiatric disorders by detailed study of endophenotypes in first and second degree relatives.
(ii) To identify heterogeneous disease subcohorts based on genomic signatures, including those that overlap between ALS and neuropsychiatric illness.